Tag: FDA biosimilars
Biosimilar Approval: How the FDA Reviews Biologic Alternatives in 2026
The FDA's 2025 guidance streamlines biosimilar approval by replacing costly clinical trials with advanced analytical data, accelerating access to lower-cost biologic alternatives for cancer, arthritis, and diabetes. Learn how the process works and what's still holding it back.
view morerecent posts
Edema in CKD is caused by fluid buildup from failing kidneys. Managing it requires a three-part strategy: the right diuretics, strict salt restriction, and compression therapy. Learn how each works-and how to use them safely.
Published ON: 7 FebStatin-related liver enzyme elevations are common but rarely dangerous. Learn when to worry, when to ignore, and why stopping your statin over a lab result could put your heart at risk.
Published ON: 2 FebMost workplace wellness programs fail because employees don’t understand how they benefit. Learn how to educate staff with clear, personalized messaging that boosts participation, cuts costs, and builds trust.
Published ON: 1 FebPolycystic kidney disease is a genetic disorder causing cysts to grow in the kidneys, leading to kidney failure. Learn how ADPKD and ARPKD work, how to manage symptoms, and what new treatments are on the horizon.
Published ON: 7 FebHyponatremia and hypernatremia are common, dangerous complications in kidney disease. Learn how sodium imbalances happen, why standard treatments fail, and what actually works to protect your health.
Published ON: 8 Feb